Resmetirom for MASH in Pakistani patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 4 interventional trial conducted at the Liver Transplant Center, Holy Family Hospital in Rawalpindi that gives resmetirom to patients with fibroscan‑proven MASH and metabolic comorbidities. Eligibility requires objective liver stiffness or steatosis measures (e.g., LSM ≥ 8.5 kPa, FAST ≥ 0.67, CAP ≥ 275 dB/m, or FIB‑4 > 1.3) and at least one metabolic condition such as type 2 diabetes, obesity, dyslipidemia, or hypertension. Key exclusions include cirrhosis, decompensated liver disease, chronic viral or other non‑MASH liver disease, recent resmetirom use, significant renal impairment, pregnancy, active substance abuse, and recent major cardiovascular events. Participants will be monitored for safety and changes in liver biomarkers and noninvasive fibrosis/steatosis measures while receiving resmetirom.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)

  * Clinical diagnosis of MASH using:

    * LSM ≥ 8.5kpa And/or
    * FAST score ≥0.67 And/or
    * FibroScan CAP ≥ 275 dB/m And/or
    * FIB-4 \> 1.3

Exclusion Criteria:

* • History of drug addiction and alcoholism

  * Cirrhosis or decompensated liver disease
  * Chronic viral hepatitis HBV, HCV)
  * MACE including MI, Stroke, PE etc.
  * Pregnant/lactating women
  * Concurrent use of other investigational drugs
  * History of other liver diseases (viral, autoimmune, drug-induced, alcohol)
  * Previous use of resmetirom in last 6 months
  * Significant renal impairment (eGFR \<30)

Where it's running

• Liver transplant center, Holy family hospital
  Rawalpindi, Punjab Province, Pakistan Recruiting

Study contacts

• Study coordinator: Hussain B Abidi, MBBS, MBA, CRCP
• Email: MDR.hussainabidi@gmail.com
• Phone: +923322583236

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rezdiffra with diabetes and pioglitazone or dapagliflozin in adults with MASH and F2-F3 fibrosis

  This study tests whether Rezdiffra (resmetirom) can be safely used together with common diabetes medicines in adults with MASH and moderate to advanced liver fibrosis.

  Recruiting at 3 sites Phase 4 Madrigal Pharmaceuticals, Inc. · Chandler, Arizona and 15 other locations · NCT07848191

• Resmetirom for MASH with HFpEF in adults

  This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.

  Recruiting at 5 sites Phase 1 Madrigal Pharmaceuticals, Inc. · Peoria, Arizona and 4 other locations · NCT07830758

• MWN105 injection in overweight or obese adults you may join

  This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.

  Recruiting Phase 1 Shanghai Minwei Biotechnology Co., Ltd · Kunming, Yunnan · NCT07803809

• Resmetirom in children and teens with MASH

  This study tests how safe resmetirom is and how it acts in the body of kids aged 6 to 17 who have MASH with liver fibrosis.

  Recruiting Phase 2 Madrigal Pharmaceuticals, Inc. · Indianapolis, Indiana · NCT07763015

• Liver Inflammation Index test for MASH in adults with T2DM and MAFLD

  This study tests a Liver Inflammation Index to see if it can identify MASH in adults who have both type 2 diabetes and MAFLD.

  Recruiting at 22 sites The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Bengbu, Anhui and 21 other locations · NCT07632677

• HSK31679 in MASH: a phase 3 test for safety and liver improvement

  This phase 3 trial tests whether HSK31679 helps people with MASH compared to a placebo.

  Recruiting Phase 3 Haisco Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality · NCT07581951

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.